Skip to Content


Sherman Appointed New Chair of Endocrine Neoplasia,Hormonal Disorders at M. D. Anderson

Sherman Appointed New Chair of Endocrine Neoplasia,Hormonal Disorders at M. D. Anderson
M. D. Anderson Cancer Center 12/27/04

Steven I. Sherman, M.D.,has been named the chair of the department of endocrine neoplasia and hormonal disorders at The University of Texas M. D. Anderson Cancer Center.

Sherman joined the M. D. Anderson faculty in 1993 from Johns Hopkins University School of Medicine where he earned his medical degree. He completed an internship, residency and fellowship in medicine during his time at Johns Hopkins and later went on to serve as an assistant professor of medicine.

An internationally recognized expert on thyroid carcinoma, Sherman has dedicated his career to understanding diseases of the thyroid gland through developing and implementing clinical trials that test new therapeutic drugs, as well as working to identify more effective approaches to treating patients with cancer.

“Working at M. D. Anderson has provided me with the unique opportunity to interact with an incredibly motivated group of patients—many of whom travel from all over the world seeking innovative treatment options and pursuing the chance to participate in a clinical trial for thyroid cancer, even those with advanced disease,” Sherman said.

Sherman has served as ad interim chair of the department for the past four years. During that time, he helped to expand the first multi-institutional study group for papillary thyroid carcinoma, a consortium he now leads. He also developed numerous clinical trials for  thyroid cancer. Within his new role, Sherman plans to focus his efforts in four areas: enhancing clinical research programs, targeting endocrine malignancies, recruiting faculty to explore diabetes in cancer care and expanding collaborations with various medical institutions.

Sherman has held many leadership roles throughout his career. For the past five years, he has chaired the Thyroid Cancer Panel for the National Comprehensive Cancer Network Guidelines Program and since 1998 has been the director of the National Thyroid Cancer Treatment Cooperative Study group. Most recently, in September, he was named director of the Executive Council of the American Thyroid Association, the leading professional society of physicians and researchers who specialize in disease of the thyroid gland.

© 2015 The University of Texas MD Anderson Cancer Center